Pays: Australie
Langue: anglais
Source: APVMA (Australian Pesticides and Veterinary Medicines Authority)
THIOMERSAL; SELENIUM; CLOSTRIDIUM CHAUVOEI - TOXOID; CLOSTRIDIUM NOVYI TYPE B - TOXOID; CLOSTRIDIUM PERFRINGENS TYPE D TOXOID; CLOSTRIDIUM SEPTICUM - TOXOID; TETANUS = CLOSTRIDIUM TETANI
ZOETIS AUSTRALIA PTY LTD
Cl perfringens toxoid (D)(5IU/mL)+Cl tetani - toxoid(2.5IU/mL) + others
PARENTERAL LIQUID/SOLUTION/SUSPENSION
THIOMERSAL MERCURY Active 0.1 mg/ml; SELENIUM MINERAL-SELENIUM Active 1.0 mg/ml; CLOSTRIDIUM CHAUVOEI - TOXOID VACCINE-TOXOID Active 0.0 P; CLOSTRIDIUM NOVYI TYPE B - TOXOID VACCINE-TOXOID Active 0.0 P; CLOSTRIDIUM PERFRINGENS TYPE D TOXOID VACCINE-TOXOID Active 0.0 P; CLOSTRIDIUM SEPTICUM - TOXOID VACCINE-TOXOID Active 0.0 P; TETANUS = CLOSTRIDIUM TETANI VACCINE-TOXOID Active 0.0 P
250mL
VM - Veterinary Medicine
ZOETIS AUSTRALIA
LAMB | SHEEP | EWE | HOGGET | LAMB | OVINE | RAM | WEANER | WETHER
IMMUNOTHERAPY
BLACK DISEASE | BLACKLEG | ENTEROTOXAEMIA (PULPY KIDNEY) | MALIGNANT OEDEMA | TETANUS | WHITE MUSCLE DISEASE | CLOSTRIDIUM PERFRINGENS TYPE D | SELENIUM DEFICIENCY | STIFF LAMB DISEASE | SUBACUTE ENZOOTIC MUSCULAR DYS | TETANUS VACCINATION
Poison schedule: 6; Withholding period: WHP: Nil TRADE ADVICE: EXPORT SLAUGHT ER INTERVAL (ESI): ESI not applicable.; Host/pest details: LAMB: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, WHITE MUSCLE DISEASE]; SHEEP: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS]; Poison schedule: 6; Withholding period: ; Host/pest details: LAMB: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, WHITE MUSCLE DISEASE]; SHEEP: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS]; For the prevention of enterotoxaemia (pulpy kidney), tetanus, black disease, malignant oedema (blackleg like disease) and blackleg in sheep and lambs and the prevention of white muscle disease in lambs after they have been vaccinated at marking.See CAUTION - AVOID CARCASE DAMAGE on label.
Registered
2023-07-01
APPENDIX2 Australian Government Australian Pesticides and Veterinary Medicines Authority + TEMPLATE FOR RELEVANT LABEL PARTICULARS (RLPs) (Veterinary Prodlltetg) Select appropriate: RLP Approved [J New Product (include all applicable RLPs) OR 00 Variation (highlight instructions that are being 48866/0509 varied). Approval no. of label being varied: Signal heading: Product name: Active constituent/s: Statement of claims: Net contents: Directions for Use Heading: Restraints: Contraindications: Precautions: Side effects: Dosage & administration: POISON KEEP PUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Ultravac® 5 in 1 S with Selenium for Lambs Vaccine Ultravacqi)S in 1 S with Selenium for Lambs Vaccine is a multicomponent adjuvant vaccine containing ultrafiltered antigens of ~ 5 IU/mL Clostridium perfringens type D, ~ 2.5 IU/mL Cl. tetani, ~ 3.5 IU/mL Cl. novyi type B, ~ 2.5 IU/mL Cl. septicum and formol culture of ~ 0.33 mL!mL Cl. chauvoei. It also contains 2.4 mg/mL sodium selenate (equivalent to 1 mg of elemental selenium per 1 mL dose). The adjuvant, which is an aluminium salt, increases the level and duration of the immunity conferred by the vaccine. The type of adjuvant and the purification procedures used ensure maximum protection of stock with minimum risk of local reactions at the site of injection. Thiomersal 0.1 mg/mL is added as a preservative .. For the prevention of enterotoxaemia (pulpy kidney disease}, tetanus, black disease, malignant oedema (blackleg- like disease) and blackleg in sheep and lambs and the prevention of white muscle disease in lambs after they have been vaccinated at marking 250 mL DIRECTIONS FOR USE READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT Contents must be left in outer package until immediately before use. Shake well before use and keep thoroughly mixed during use. It is important that the vaccine is kept properly mixed before and during use. N/A N/A N/A Localised swelling may develop at the site of injection and a firm nodular lump may persist for some weeks or e Lire le document complet
ULTRAVAC™ 5 IN 1 VACCINE 5MG SELENIUM (New Zealand Only) Material Safety Data Sheet 0011 Date of Issue: Tue 24 September 2002 ------------------------------------------------------------------------------------------------------------------------------------------------ IDENTIFICATION ------------------------------------------------------------------------------------------------------------------------------------------------ STATEMENT OF HAZARDOUS NATURE _Classified as hazardous according to Worksafe Australia criteria_ SUPPLIER Company: CSL Limited (Animal Health Division) (ABN 99 051 588 348) Address: 45 Poplar Road Parkville, Victoria 3052 Australia Telephone: 1800 333 011 Emergency Tel: (03) 9389 1984 Fax: (03) 9389 1646 Product Name: Ultravac™ 5 in 1 with Selenium Other Names: Cl. perfringens Type D, Cl. tetani, Cl. septicum, Cl. novyi Type B, Cl. chauvoei Vaccine with Selenium Product Code: 0011 CAS RN No(s): None UN Number: None Dangerous Goods Class: None Subsidiary Risk: None Hazchem Code: None Poisons Schedule Number: NZS2 USE _For the prevention of clostridial diseases in sheep_ _in areas of selenium deficiency_ Administer by Injection PHYSICAL DESCRIPTION/PROPERTIES Appearance: Aqueous liquid suspension Boiling Point (deg C): 100 Melting Point (deg C): 0 Vapour Pressure (kPa): 3.19 @25C Specific Gravity: 1.01 Flash Point (deg C): Not applicable Lower Explosive Limit (%): Not applicable Upper Explosive Limit (%): Not applicable Solubility in Water (g/L): Miscible INGREDIENTS Name CAS RN % Saline suspension >90 Containing ultrafiltered, Cl. perfringens Type D Toxoid Cl. tetani Toxoid Cl. novyi Type B Toxoid Cl. septicum Toxoid Page 1/4 And formol culture of Cl. chauvoei (in amounts sufficient in balanced proportion to satisfy potency requirements of BP(Vet) 1993) Sodium selenate, decahydrate 10102-23-5 0.60 Adjuvant <0.4 Preservative 54-64-8 0.01 ------------------------------------------------------------------------------------------------------------------------------------------------ HEALTH H Lire le document complet